This study is testing a new way to deliver human insulin for people with Type 2 Diabetes. Instead of injections, insulin is delivered through the skin using a finger-actuated pump sprayer. Researchers want to see how well this transdermal (through the skin) human insulin works to control blood sugar compared to traditional injected insulin. The study will measure the percentage of time participants' blood sugar stays within a healthy range over 21 days. They are looking for 30 adults, aged 25 to 75, who currently manage their Type 2 Diabetes with insulin injections and have well-controlled blood sugar levels.

Study design

This is an open-label study, meaning both participants and researchers will know which treatment is being given. It will involve 30 participants with Type 2 Diabetes.

What's involved

You would be monitored with a Continuous Glucose Monitor (CGM) for two weeks before starting the transdermal insulin. During the 21-day study, you'll use the transdermal insulin and continue CGM monitoring, calibrating it with finger-stick tests every 8 hours. You will also be monitored for 7 days after your last transdermal dose.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for 7 days after the last transdermal dose.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.